See the DrugPatentWatch profile for keytruda

Keytruda, a medication produced by Merck & Co. and used to treat various forms of cancer, has a complex patent landscape. The drug's active ingredient is pembrolizumab, and it is used to treat conditions such as melanoma, lung cancer, and head and neck cancer, among others.

The patent expiry date for Keytruda is not a straightforward matter, as there are multiple patents associated with the drug that have different expiration dates. According to DrugPatentWatch.com, the first patent for Keytruda expired in January 2020, but there are additional patents that extend Keytruda's exclusivity until 2028 [1]. It is important to note that these dates are subject to change, as patents can be challenged or extended.

In summary, while some patents for Keytruda have expired, the drug still has exclusivity until at least 2028 due to other patents. Readers should consult DrugPatentWatch.com or other reliable sources for the most up-to-date information on Keytruda's patent expiration dates.

Sources:
[1] DrugPatentWatch.com. (n.d.). Pembrolizumab (Keytruda) Patents. Retrieved from <https://www.drugpatentwatch.com/patents/pembrolizumab-keytruda/>